Could cord blood transplants slow ALS? new trial begins

NCT ID NCT07539662

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early trial tests whether a transplant of umbilical cord blood can help people with ALS, a fast-progressing nerve disease. Eight adults will receive the transplant after a mild chemotherapy-like prep. Researchers will check safety and whether the treatment slows decline in muscle strength, breathing, and daily function over 24 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
umbilical cord blood transplant
What this could lead to
If it works, this could point toward a new way to slow ALS by calming brain inflammation and repairing nerve damage.
What could go wrong
This is a very early, small trial with only 8 people, so results may not apply widely. The transplant itself carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS - AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.